TORONTO, Feb. 2 /CNW/ - Amorfix Life Sciences Ltd. reported today that it has obtained an exclusive worldwide license to novel targets on Superoxide Dismutase-1 (SOD1), which is a protein known to misfold and aggregate in the neurological disease Amyotrophic Lateral Sclerosis (ALS). The company also obtained an exclusive five-year option to acquire the intellectual property and know how surrounding the licensed technology. The company will use these novel targets to initiate its therapeutic program for neurodegenerative diseases, beginning with ALS.
